ALK and anaplastic large cell lymphoma: Given the exceeding rarity of CNS‐positive ALCL, the current poor outcome, the risk for acute toxicity and the late effects of the front‐line therapy, there is an urgent need to test CNS‐penetrable ALK inhibitors in front‐line therapy of CNS‐positive ALCL patients.